TY - JOUR
T1 - Systemic therapy
AU - Wolff, Antonio C.
PY - 2000/12/1
Y1 - 2000/12/1
N2 - Our knowledge base on systemic therapy for breast cancer continues to expand, including further information regarding hormonal prevention in high-risk women, beneficial effects of tamoxifen in noninvasive disease, an update on primary systemic therapy, and optimization of adjuvant strategies, including data on adjuvant chemoendocrine regimens. The proper evaluation of high-dose strategies has been jeopardized by a serious episode of scientific misconduct. New data are also available on palliative options, bisphosphonates, antibody therapies, and novel targets. Data continue to evolve on the role and optimal schedules of taxanes in early-stage and advanced breast cancer. These and other important recent findings are discussed in this review article.
AB - Our knowledge base on systemic therapy for breast cancer continues to expand, including further information regarding hormonal prevention in high-risk women, beneficial effects of tamoxifen in noninvasive disease, an update on primary systemic therapy, and optimization of adjuvant strategies, including data on adjuvant chemoendocrine regimens. The proper evaluation of high-dose strategies has been jeopardized by a serious episode of scientific misconduct. New data are also available on palliative options, bisphosphonates, antibody therapies, and novel targets. Data continue to evolve on the role and optimal schedules of taxanes in early-stage and advanced breast cancer. These and other important recent findings are discussed in this review article.
UR - http://www.scopus.com/inward/record.url?scp=0034522450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034522450&partnerID=8YFLogxK
U2 - 10.1097/00001622-200011000-00004
DO - 10.1097/00001622-200011000-00004
M3 - Review article
C2 - 11085452
AN - SCOPUS:0034522450
SN - 1040-8746
VL - 12
SP - 532
EP - 540
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 6
ER -